Skip to main content
Top
Published in: Clinical Orthopaedics and Related Research® 3/2009

01-03-2009 | Original Article

β-Catenin Overexpression in Dupuytren’s Disease Is Unrelated to Disease Recurrence

Authors: Ilse Degreef, MD, Luc De Smet, MD, PhD, Raf Sciot, MD, PhD, Jean-Jacques Cassiman, MD, PhD, Sabine Tejpar, MD, PhD

Published in: Clinical Orthopaedics and Related Research® | Issue 3/2009

Login to get access

Abstract

Recurrence of Dupuytren’s contracture is common yet unpredictable, compromising surgical outcome. The α-smooth muscle actin-containing myofibroblast is the active contractile cellular component. Based on recent reports on β-catenin accumulation in Dupuytren’s disease, we investigated a possible relation with disease recurrence. We divided a collection of 143 nodules into those from patients with recurrent or nonrecurrent nodules and with a minimal 3-year followup. We randomly selected 12 and 11 samples of each group, respectively. We looked at Dupuytren’s diathesis, immunohistologic staining for β-catenin and α-smooth muscle actin, and Luck’s histologic stages (zones). The expression of selected Wnt genes was examined with TaqMan® PCR in separate histologic zones. All samples showed cytoplasmic and nuclear β-catenin accumulation in myofibroblasts in involutional zones. The risk score of Abe et al. and Dupuytren’s diathesis were greater in the recurrent group. Greater Wnt5a expression in the β-catenin-accumulating involutional zone was seen. We conclude intracellular β-catenin accumulation, possibly regulated by upstream Wnt signaling pathway activation and confined in myofibroblasts in the involutional zone of Dupuytren’s diathesis, is unrelated to disease recurrence. Clinical parameters for Dupuytren’s diathesis remain the best way to predict recurrence risk.
Literature
1.
go back to reference Abe Y, Rokkaku T, Ofuchi S, Tokunaga S, Takahashi K, Moriya H. An objective method to evaluate the risk of recurrence and extension of Dupuytren’s disease. J Hand Surg Br. 2004;29:427–430.PubMed Abe Y, Rokkaku T, Ofuchi S, Tokunaga S, Takahashi K, Moriya H. An objective method to evaluate the risk of recurrence and extension of Dupuytren’s disease. J Hand Surg Br. 2004;29:427–430.PubMed
2.
go back to reference Aitchison J. The statistical analysis of compositional data. J R Stat Soc B. 1982;44:139–177. Aitchison J. The statistical analysis of compositional data. J R Stat Soc B. 1982;44:139–177.
3.
go back to reference Al-Qattan MM. Factors in the pathogenesis of Dupuytren’s contracture. J Hand Surg Am. 2006;31:1527–1534.PubMedCrossRef Al-Qattan MM. Factors in the pathogenesis of Dupuytren’s contracture. J Hand Surg Am. 2006;31:1527–1534.PubMedCrossRef
4.
go back to reference Bowley E, O’Gorman DB, Gan BS. Beta-catenin signalling in fibroproliferative disease. J Surg Res. 2007;138:141–150.PubMedCrossRef Bowley E, O’Gorman DB, Gan BS. Beta-catenin signalling in fibroproliferative disease. J Surg Res. 2007;138:141–150.PubMedCrossRef
5.
go back to reference Bulstrode NW, Jemec B, Smith PJ. The complications of Dupuytren’s contracture surgery. J Hand Surg Am. 2005;30:1021–1025.PubMedCrossRef Bulstrode NW, Jemec B, Smith PJ. The complications of Dupuytren’s contracture surgery. J Hand Surg Am. 2005;30:1021–1025.PubMedCrossRef
6.
go back to reference Cordova A, Tripoli M, Corradino B, Napoli P, Moschella F. Dupuytren’s contracture: an update of biomolecular aspects and therapeutic perspectives. J Hand Surg Br. 2005;30:557–562.PubMed Cordova A, Tripoli M, Corradino B, Napoli P, Moschella F. Dupuytren’s contracture: an update of biomolecular aspects and therapeutic perspectives. J Hand Surg Br. 2005;30:557–562.PubMed
7.
go back to reference Dias JJ, Braybrooke J. Dupuytren’s contracture: an audit of the outcomes of surgery. J Hand Surg Br. 2006;31:514–521.PubMedCrossRef Dias JJ, Braybrooke J. Dupuytren’s contracture: an audit of the outcomes of surgery. J Hand Surg Br. 2006;31:514–521.PubMedCrossRef
8.
go back to reference Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200:500–503.PubMedCrossRef Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200:500–503.PubMedCrossRef
9.
go back to reference Hindocha S, John S, Stanley JK, Watson SJ, Bayat A. The heritability of Dupuytren’s disease: familial aggregation and its clinical significance. J Hand Surg Am. 2006;31:204–210.PubMedCrossRef Hindocha S, John S, Stanley JK, Watson SJ, Bayat A. The heritability of Dupuytren’s disease: familial aggregation and its clinical significance. J Hand Surg Am. 2006;31:204–210.PubMedCrossRef
10.
go back to reference Hindocha S, Stanley JK, Watson S, Bayat A. Dupuytren’s diathesis revisited: evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg Am. 2006;31:1626–1634.PubMedCrossRef Hindocha S, Stanley JK, Watson S, Bayat A. Dupuytren’s diathesis revisited: evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg Am. 2006;31:1626–1634.PubMedCrossRef
11.
go back to reference Howard JC, Varallo VM, Ross DC, Roth JH, Faber KJ, Alman B, Gan BS. Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren’s disease cells are regulated by tension in vitro. BMC Musculoskelet Disord. 2003;4:16.PubMedCrossRef Howard JC, Varallo VM, Ross DC, Roth JH, Faber KJ, Alman B, Gan BS. Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren’s disease cells are regulated by tension in vitro. BMC Musculoskelet Disord. 2003;4:16.PubMedCrossRef
12.
go back to reference Iwasaki H, Müller H, Stutte HJ, Brennscheidt U. Palmar fibrosis (Dupuytren’s contracture). Virchows Arch A Pathol Anat Histopathol. 1984;405:41–53.PubMedCrossRef Iwasaki H, Müller H, Stutte HJ, Brennscheidt U. Palmar fibrosis (Dupuytren’s contracture). Virchows Arch A Pathol Anat Histopathol. 1984;405:41–53.PubMedCrossRef
14.
go back to reference Luck V. Dupuytren’s contracture. J Bone Joint Surg Am. 1959;41:635–664.PubMed Luck V. Dupuytren’s contracture. J Bone Joint Surg Am. 1959;41:635–664.PubMed
15.
go back to reference McFarlane RM, McGrouther DA, Flint MH. Dupuytren’s Disease. New York, NY: Churchill Livingstone; 1990. McFarlane RM, McGrouther DA, Flint MH. Dupuytren’s Disease. New York, NY: Churchill Livingstone; 1990.
16.
go back to reference Meister P, Gokel JM, Remberger K. Palmar fibrosis—“Dupuytren’s contracture”: a comparison of light electron and immunofluorescence microscopic findings. Pathol Res Pract. 1979;164:402–412.PubMed Meister P, Gokel JM, Remberger K. Palmar fibrosis—“Dupuytren’s contracture”: a comparison of light electron and immunofluorescence microscopic findings. Pathol Res Pract. 1979;164:402–412.PubMed
17.
go back to reference Montgomery E, Folpe AL. The diagnostic value of beta-catenin immunohistochemistry. Adv Anat Pathol. 2005;12:350–356.PubMedCrossRef Montgomery E, Folpe AL. The diagnostic value of beta-catenin immunohistochemistry. Adv Anat Pathol. 2005;12:350–356.PubMedCrossRef
18.
go back to reference Montgomery E, Lee JH, Abraham SC, Wu TT. Superficial fibromatosis are genetically different from deep fibromatoses. Mod Pathol. 2001;14:695–701.PubMedCrossRef Montgomery E, Lee JH, Abraham SC, Wu TT. Superficial fibromatosis are genetically different from deep fibromatoses. Mod Pathol. 2001;14:695–701.PubMedCrossRef
19.
go back to reference O’Gorman DB, Wu Y, Seney S, Zhu RD, Gan BS. Wnt expression is not correlated with beta-catenin dysregulation in Dupuytren’s disease. J Negat Results Biomed. 2006;5:13.PubMedCrossRef O’Gorman DB, Wu Y, Seney S, Zhu RD, Gan BS. Wnt expression is not correlated with beta-catenin dysregulation in Dupuytren’s disease. J Negat Results Biomed. 2006;5:13.PubMedCrossRef
20.
go back to reference Rombouts JJ, Noël H, Legrain Y, Munting E. Prediction of recurrence in the treatment of Dupuytren’s disease: evaluation of a histologic classification. J Hand Surg Am. 1989;14:644–652.PubMedCrossRef Rombouts JJ, Noël H, Legrain Y, Munting E. Prediction of recurrence in the treatment of Dupuytren’s disease: evaluation of a histologic classification. J Hand Surg Am. 1989;14:644–652.PubMedCrossRef
21.
go back to reference Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, Van Cutsem E, Bapat B, van Roy F, Cassiman JJ, Alman BA. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18:6615–6620.PubMedCrossRef Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, Van Cutsem E, Bapat B, van Roy F, Cassiman JJ, Alman BA. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18:6615–6620.PubMedCrossRef
22.
go back to reference Teo R, Mohrlen F, Plickert G, Muller WA, Frank U. An evolutionary conserved role of Wnt signaling in stem cell fate decision. Dev Biol. 2006;289:91–99.PubMedCrossRef Teo R, Mohrlen F, Plickert G, Muller WA, Frank U. An evolutionary conserved role of Wnt signaling in stem cell fate decision. Dev Biol. 2006;289:91–99.PubMedCrossRef
23.
go back to reference Tomasek J, Rayan GM. Correlation of alpha-smooth muscle actin expression and contraction in Dupuytren’s disease fibroblasts. J Hand Surg Am. 1995;20:450–455.PubMedCrossRef Tomasek J, Rayan GM. Correlation of alpha-smooth muscle actin expression and contraction in Dupuytren’s disease fibroblasts. J Hand Surg Am. 1995;20:450–455.PubMedCrossRef
24.
go back to reference Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3:349–363.PubMedCrossRef Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3:349–363.PubMedCrossRef
25.
go back to reference Varallo VM, Gan BS, Seney S, Ross DC, Roth JH, Richerds RS, McFarlane RM, Alman B, Howard JC. Beta-catenin expression in Dupuytren’s disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene. 2003;22:3680–3684.PubMedCrossRef Varallo VM, Gan BS, Seney S, Ross DC, Roth JH, Richerds RS, McFarlane RM, Alman B, Howard JC. Beta-catenin expression in Dupuytren’s disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene. 2003;22:3680–3684.PubMedCrossRef
26.
go back to reference Wilbrand S, Flodmark C, Ekborm A, Gerdin B. Activation markers of connective tissue in Dupuytren’s contracture: relation to postoperative outcome. Scand J Plast Reconstr Surg Hand Surg. 2003;37:283–292.PubMedCrossRef Wilbrand S, Flodmark C, Ekborm A, Gerdin B. Activation markers of connective tissue in Dupuytren’s contracture: relation to postoperative outcome. Scand J Plast Reconstr Surg Hand Surg. 2003;37:283–292.PubMedCrossRef
Metadata
Title
β-Catenin Overexpression in Dupuytren’s Disease Is Unrelated to Disease Recurrence
Authors
Ilse Degreef, MD
Luc De Smet, MD, PhD
Raf Sciot, MD, PhD
Jean-Jacques Cassiman, MD, PhD
Sabine Tejpar, MD, PhD
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Clinical Orthopaedics and Related Research® / Issue 3/2009
Print ISSN: 0009-921X
Electronic ISSN: 1528-1132
DOI
https://doi.org/10.1007/s11999-008-0590-z

Other articles of this Issue 3/2009

Clinical Orthopaedics and Related Research® 3/2009 Go to the issue

Symposium: Femoroacetabular Impingement: Current Status of Diagnosis and Treatment

Do Normal Radiographs Exclude Asphericity of the Femoral Head-Neck Junction?

Symposium: Femoroacetabular Impingement: Current Status of Diagnosis and Treatment

Complications of Arthroscopic Femoroacetabular Impingement Treatment: A Review

Symposium: Femoroacetabular Impingement: Current Status of Diagnosis and Treatment

Radiographic Evaluation of the Hip has Limited Reliability

Symposium: Femoroacetabular Impingement: Current Status of Diagnosis and Treatment

Capital Realignment for Moderate and Severe SCFE Using a Modified Dunn Procedure